<DOC>
	<DOCNO>NCT00749346</DOCNO>
	<brief_summary>An open-label phase I-II trial perform 42 patient pretreated locally advanced non-small cell lung cancer . The trial design estimate efficacy determine safety NovoTTF-100L treatment combine Pemetrexed advance NSCLC patient . Patients receive standard Pemetrexed therapy ( 500 mg/m2 iv q3w 3 cycle ) concomitant NovoTTF-100L therapy ( 12 hour day , daily end three cycle Alimta ) . Repeat treatment Alimta + NovoTTF-100L offer long patient stable responding . If in-field response progression outside NovoTTF field , Pemetrexed stop third line chemotherapy Docetaxel initiate ( 35 mg/m2 weekly , d1 , 8 , 15 , q 28 ) .</brief_summary>
	<brief_title>NovoTTF-100L Combination With Pemetrexed ( Alimta® ) Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>The trial conduct two stage . Fourteen patient recruit phase I stage trial . After 14 patient receive 3 course Alimta ( 9 week NovoTTF-100L treatment ) , patient analyze toxicity . If incidence device relate serious adverse event &lt; 20 % , trial continue second stage 42 patient assessed safety efficacy part phase II study ( include first 14 patient phase I study ) . Efficacy assess base local disease control lungs liver , time systemic disease progression , overall survival . Patients follow least 6 month last course NovoTTF-100L apply assess survival .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IV IIIB malignant pleural effusion , also locally advanced NSCLC otherwise amenable local treatment ( surgery radiotherapy ) One line prior chemotherapy Measurable disease Greater equal 18 year Life expectancy least 12 week ECOG performance status 02 Laboratory requirement entry : Blood cell count : Absolute neutrophils ≥ 1.0 x 109/L Platelets ≥100 x 109/L Hemoglobin ≥ 10 g/dl Renal function : Creatinine clearance ≥ 45 mL/min Hepatic function : ASAT ALAT ≤ 3 x UNL Alkaline phosphatase ≤ 5 x UNL Signed informed consent prior start protocol specific requirement Pregnancy test ( βHCG ) must negative ( need woman childbearing potential ) . Known brain metastasis meningeal carcinomatosis Other serious concomitant illness medical condition : Congestive heart failure angina pectoris except medically control . Previous history myocardial infarction within 1 year study entry . Uncontrolled hypertension arrhythmia Implanted pacemaker , defibrillator deep brain stimulation device History significant neurologic psychiatric disorder include dementia seizure Active infection require iv antibiotic Active ulcer , unstable diabetes mellitus contraindication corticosteroid therapy Concurrent treatment experimental drug Participation clinical trial experimental agent within 30 day study entry Psychological , familial , sociological geographical condition n't permit medical followup compliance study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>TTFields</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Alimta</keyword>
	<keyword>Pemetrexed</keyword>
</DOC>